Science
Unpredicted binding found between SARS-CoV-2 and hepatitis C drug, telaprevir – Drug Target Review
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Posted: 24 March 2021 | Victoria Rees (Drug Target Review) | No comments yet
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Scientists have found new, unexpected behaviours when SARS-CoV-2 – the virus that causes COVID-19 – encounters drug inhibitors, which bind to certain components of the virus and block its ability to reproduce.
According to the team, from the US Department of Energy’s Oak Ridge National…
-
Business20 hours agoZip shares rocketed 32% in August. Here’s how
-
Business22 hours agoGold price alert! Macquarie reveals its top ASX 200 gold stock as the metal hits all-time high
-
Business18 hours agoDown more than 20% this year, does Macquarie rate Boss Energy shares a buy?
-
General19 hours agoKids unknowingly targeted with AI abuse apps, images